IP Library Granted Patent US 8,177,778
Granted Patent B2
US 8,177,778 · App. 12/915,646 · Granted May 15, 2012

System and method for stabilizing corneal tissue after treatment

Assignee: Avedro, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,177,778
App. No.
12/915,646
Granted
May 15, 2012
Kind
B2
Abstract

Systems and methods stabilize corneal tissue after treatment of the corneal tissue. For example, thermokeratoplasty may be applied to the corneal tissue to address disorders associated with abnormal shaping of the cornea. To stabilize the desired structural changes caused by the treatment, embodiments apply ophthalmic formulations that help to inhibit wound healing. Wound healing may occur in response to the application of the treatment and may produce further structural changes that mitigate or alter the desired effects of the treatment.

Claims (19)

1. A system for applying therapy to an eye, the system comprising:

an electrical energy source;

an electrical energy conducting element in contact with the electrical energy source, the electrical energy conducting element having a proximal end configured to receive electrical energy generated by the electrical energy source, and a distal end configured to apply electrical energy;

a wound healing inhibitor including Mannose 6-phosphate (M6P), the wound healing inhibitor being configured to reduce corneal haze by competing with latent Transforming Growth Factor beta (TGFb) at an Insulin Like Growth Factor II receptor;

a wound healing inhibitor delivery element in contact with the wound healing inhibitor;

a processor configured to determine Transforming Growth Factor beta (TGFb) activity,

a coolant supply; and

a coolant delivery element in contact with the coolant supply, the coolant delivery element configured to deliver a pulse of coolant

wherein the wound healing inhibitor delivery element is adjusted based on the Transforming Growth Factor beta (TGFb) activity.

2. The system according to claim 1 , wherein the wound healing inhibitor delivery element is at least one of an eye dropper and a drug application device configured to be removably attached to the eye.

3. The system according to claim 1 , wherein the electrical energy is microwave energy.

4. A system for applying therapy to an eye, the system comprising:

an electrical energy source;

an electrical energy conducting element in contact with the electrical energy source, the electrical energy conducting element having a proximal end configured to receive electrical energy generated by the electrical energy source, and a distal end configured to apply electrical energy;

a wound healing inhibitor delivery element including a wound healing inhibitor, the wound healing inhibitor including Mannose 6-phosphate (M6P); and

a processor configured to determine Transforming Growth Factor beta (TGFb) activity,

wherein the wound healing inhibitor delivery element is adjusted based on the Transforming Growth Factor beta (TGFb) activity.

5. The system according to claim 4 , wherein the wound healing inhibitor delivery element is at least one of an eye dropper and a drug application device configured to be removably attached to the eye.

6. The system according to claim 4 , wherein the electrical energy is microwave energy.

Assignments (2)
SECURITY AGREEMENT Recorded Feb 13, 2012
From: AVEDRO, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 027697/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2011
From: MULLER, DAVID; MARSHALL, JOHN
To: AVEDRO, INC.
Reel/Frame 025711/0807 →
Continuity (2)
Provisional Application 61256714 · Oct 30, 2009
Related Publication 20110118716A1 · May 19, 2011